Interventional Testing of Gene-environment Interactions Via the Verifomics Mobile Application

NCT ID: NCT02758990

Last Updated: 2017-10-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-03-31

Study Completion Date

2016-11-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to study interactions between genes, lifestyle environmental factors like foods, nutritional supplements and non-invasive medical devices and health factors that can be measured without specialized medical equipment in order to develop lifestyle recommendations tailored to individual genetics for a host of common chronic health conditions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is composed of multiple interventions which will last between 2 and 6 months that evaluate a suite of predictions about the way that a given environmental factor impacts a specific health outcome based on genetic information obtained from direct-to-consumer genotyping providers (AncestryDNA and 23andMe). Substances of interest include foods, nutritional supplements and non-invasive medical devices.

A minimum of 500 subjects will be enrolled in each intervention, and only those subjects which are predicted to benefit from the intervention when considering all sites of interest will be assigned to an intervention. The predictions are based on hundreds to thousands of sites of interest at high minor allele frequency single nucleotide polymorphisms and predictions about response are derived from the aggregate genotype at all loci considered. As such each site of interest will have a built-in negative control group composed of individuals enrolled in the intervention despite a genotype at that site that does not predict a benefit. The rate that each site of interest makes correct predictions about subject response will be compared to randomly-selected sites in order to quantify placebo effects and establish quality metrics for the predictions.

Enrollment and participation are conducted remotely. Participants will upload genetic information from a direct-to-consumer provider through a mobile or web browser application, and informed consent and inclusion/exclusion criteria are accomplished remotely. After the informed consent process, participants are asked what phenotype of interest (weight, migraines, insomnia, etc.) they are interested in studying, their genetic information is evaluated and they are allowed to select an intervention they qualify for based on their genetics that they would like to participate in. Participants then answer a series of questions to establish baseline data on relevant factors as well as evaluate the inclusion and exclusion criteria; participants that qualify for the intervention are then given specific instructions on how to participate, and may then use the software to report data during the intervention. Each intervention utilizes a specific product rather than a general class of product to reduce noise from differing sourcing, distribution, storage and manufacturing practices.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity Rhinitis Rhinitis, Allergic Respiratory Sounds Dyspnea Headache Migraine Disorders Arthritis Arthralgia Anxiety Sleep Initiation and Maintenance Disorders Sleep Deprivation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Predictions: BMI vs. Broccoli

BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.

Group Type EXPERIMENTAL

Broccoli

Intervention Type OTHER

Subjects will be asked to increase broccoli intake by 8 fluid ounces (\~91 grams) per day.

Predictions: BMI vs. Caffeine

BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.

Group Type EXPERIMENTAL

Caffeine

Intervention Type DIETARY_SUPPLEMENT

Subjects will be asked to increase caffeine intake by taking 200mg caffeine orally once per day.

Predictions: BMI vs. Coffee

BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.

Group Type EXPERIMENTAL

Coffee

Intervention Type OTHER

Subjects will be asked to increase coffee intake by drinking 2 cups (177 mL each) of coffee per day.

Predictions: BMI vs. Spinach

BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.

Group Type EXPERIMENTAL

Spinach

Intervention Type OTHER

Subjects will be asked to increase spinach intake by 8 fluid ounces (\~30 grams) per day.

Predictions: BMI vs. Vitamin A

BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.

Group Type EXPERIMENTAL

Vitamin A

Intervention Type DIETARY_SUPPLEMENT

Subjects will be asked to increase vitamin A intake by 8000 International Units per day.

Predictions: BMI vs. Vitamin C

BMI will be calculated from self-reported weight (once per day) and height (at enrollment). Each gene-environment interaction of interest will be evaluated to determine its predictive power.

Group Type EXPERIMENTAL

Vitamin C

Intervention Type DIETARY_SUPPLEMENT

Subjects will be asked to increase vitamin C intake by 500 mg per day.

Predictions: Headache vs. Vitamin B6

Headache frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.

Group Type EXPERIMENTAL

Vitamin B6

Intervention Type DIETARY_SUPPLEMENT

Subjects will be asked to increase vitamin B6 intake by 50 mg per day.

Predictions: Headache vs. Vitamin C

Headache frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.

Group Type EXPERIMENTAL

Vitamin C

Intervention Type DIETARY_SUPPLEMENT

Subjects will be asked to increase vitamin C intake by 500 mg per day.

Predictions: Headache vs. Nicotinamide

Headache frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.

Group Type EXPERIMENTAL

Nicotinamide

Intervention Type DIETARY_SUPPLEMENT

Subjects will be asked to increase Nicotinamide intake by 500 mg per day.

Predictions: Headache vs. Axon Eyewear

Headache frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.

Group Type EXPERIMENTAL

Axon Eyewear

Intervention Type DEVICE

Subjects will be asked to utilize the therapeutic eyewear when exposed to bright or fluorescent light.

Predictions: Rhinitis vs Broccoli

Rhinitis frequency and severity will be self-reported on a scale from 0 to 10, with 0 indicating no rhinitis, 3 indicating minor rhinitis, 6 indicating rhinitis while preserving the ability to breathe nasally, and 10 indicating rhinitis to such a degree that mouth-breathing is required, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.

Group Type EXPERIMENTAL

Broccoli

Intervention Type OTHER

Subjects will be asked to increase broccoli intake by 8 fluid ounces (\~91 grams) per day.

Predictions: Rhinitis vs Caffeine

Rhinitis frequency and severity will be self-reported on a scale from 0 to 10, with 0 indicating no rhinitis, 3 indicating minor rhinitis, 6 indicating rhinitis while preserving the ability to breathe nasally, and 10 indicating rhinitis to such a degree that mouth-breathing is required, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.

Group Type EXPERIMENTAL

Caffeine

Intervention Type DIETARY_SUPPLEMENT

Subjects will be asked to increase caffeine intake by taking 200mg caffeine orally once per day.

Predictions: Rhinitis vs Chocolate

Rhinitis frequency and severity will be self-reported on a scale from 0 to 10, with 0 indicating no rhinitis, 3 indicating minor rhinitis, 6 indicating rhinitis while preserving the ability to breathe nasally, and 10 indicating rhinitis to such a degree that mouth-breathing is required, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.

Group Type EXPERIMENTAL

Chocolate

Intervention Type OTHER

Subjects will be asked to increase chocolate intake by eating 57g per day.

Predictions: Rhinitis vs Coffee

Rhinitis frequency and severity will be self-reported on a scale from 0 to 10, with 0 indicating no rhinitis, 3 indicating minor rhinitis, 6 indicating rhinitis while preserving the ability to breathe nasally, and 10 indicating rhinitis to such a degree that mouth-breathing is required, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.

Group Type EXPERIMENTAL

Coffee

Intervention Type OTHER

Subjects will be asked to increase coffee intake by drinking 2 cups (177 mL each) of coffee per day.

Predictions: Rhinitis vs Vitamin A

Rhinitis frequency and severity will be self-reported on a scale from 0 to 10, with 0 indicating no rhinitis, 3 indicating minor rhinitis, 6 indicating rhinitis while preserving the ability to breathe nasally, and 10 indicating rhinitis to such a degree that mouth-breathing is required, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.

Group Type EXPERIMENTAL

Vitamin A

Intervention Type DIETARY_SUPPLEMENT

Subjects will be asked to increase vitamin A intake by 8000 International Units per day.

Predictions: Insomnia vs Axon Eyewear

Sleep quality will be self-reported about the previous night's sleep on a scale from 0 to 10, with 0 indicating sleep that was not restful at all, 3 indicating mildly restful but insufficient sleep, 6 indicating a functional quality of sleep but not ideal, and 10 indicating ideal sleep, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.

Group Type EXPERIMENTAL

Axon Eyewear

Intervention Type DEVICE

Subjects will be asked to utilize the therapeutic eyewear when exposed to bright or fluorescent light.

Predictions: Insomnia vs Vitamin A

Sleep quality will be self-reported about the previous night's sleep on a scale from 0 to 10, with 0 indicating sleep that was not restful at all, 3 indicating mildly restful but insufficient sleep, 6 indicating a functional quality of sleep but not ideal, and 10 indicating ideal sleep, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.

Group Type EXPERIMENTAL

Vitamin A

Intervention Type DIETARY_SUPPLEMENT

Subjects will be asked to increase vitamin A intake by 8000 International Units per day.

Predictions: Insomnia vs Vitamin E

Sleep quality will be self-reported about the previous night's sleep on a scale from 0 to 10, with 0 indicating sleep that was not restful at all, 3 indicating mildly restful but insufficient sleep, 6 indicating a functional quality of sleep but not ideal, and 10 indicating ideal sleep, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.

Group Type EXPERIMENTAL

Vitamin E

Intervention Type DIETARY_SUPPLEMENT

Subjects will be asked to increase vitamin E intake by 400 International Units per day.

Predictions: Insomnia vs Nicotinamide

Sleep quality will be self-reported about the previous night's sleep on a scale from 0 to 10, with 0 indicating sleep that was not restful at all, 3 indicating mildly restful but insufficient sleep, 6 indicating a functional quality of sleep but not ideal, and 10 indicating ideal sleep, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.

Group Type EXPERIMENTAL

Nicotinamide

Intervention Type DIETARY_SUPPLEMENT

Subjects will be asked to increase Nicotinamide intake by 500 mg per day.

Predictions: Insomnia vs Vitamin D3

Sleep quality will be self-reported about the previous night's sleep on a scale from 0 to 10, with 0 indicating sleep that was not restful at all, 3 indicating mildly restful but insufficient sleep, 6 indicating a functional quality of sleep but not ideal, and 10 indicating ideal sleep, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.

Group Type EXPERIMENTAL

Vitamin D3

Intervention Type DIETARY_SUPPLEMENT

Subjects will be asked to increase Vitamin D3 intake by 1000 International Units per day.

Predictions: Joint pain vs Broccoli

Joint pain frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.

Group Type EXPERIMENTAL

Broccoli

Intervention Type OTHER

Subjects will be asked to increase broccoli intake by 8 fluid ounces (\~91 grams) per day.

Predictions: Joint pain vs Caffeine

Joint pain frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.

Group Type EXPERIMENTAL

Caffeine

Intervention Type DIETARY_SUPPLEMENT

Subjects will be asked to increase caffeine intake by taking 200mg caffeine orally once per day.

Predictions: Joint pain vs Coffee

Joint pain frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.

Group Type EXPERIMENTAL

Coffee

Intervention Type OTHER

Subjects will be asked to increase coffee intake by drinking 2 cups (177 mL each) of coffee per day.

Predictions: Joint pain vs Spinach

Joint pain frequency and severity will be evaluated via a graphical and written pain scale, reported once per day. Each gene-environment interaction of interest will be evaluated to determine its predictive power.

Group Type EXPERIMENTAL

Spinach

Intervention Type OTHER

Subjects will be asked to increase spinach intake by 8 fluid ounces (\~30 grams) per day.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vitamin A

Subjects will be asked to increase vitamin A intake by 8000 International Units per day.

Intervention Type DIETARY_SUPPLEMENT

Vitamin B6

Subjects will be asked to increase vitamin B6 intake by 50 mg per day.

Intervention Type DIETARY_SUPPLEMENT

Vitamin C

Subjects will be asked to increase vitamin C intake by 500 mg per day.

Intervention Type DIETARY_SUPPLEMENT

Nicotinamide

Subjects will be asked to increase Nicotinamide intake by 500 mg per day.

Intervention Type DIETARY_SUPPLEMENT

Vitamin D3

Subjects will be asked to increase Vitamin D3 intake by 1000 International Units per day.

Intervention Type DIETARY_SUPPLEMENT

Vitamin E

Subjects will be asked to increase vitamin E intake by 400 International Units per day.

Intervention Type DIETARY_SUPPLEMENT

Broccoli

Subjects will be asked to increase broccoli intake by 8 fluid ounces (\~91 grams) per day.

Intervention Type OTHER

Spinach

Subjects will be asked to increase spinach intake by 8 fluid ounces (\~30 grams) per day.

Intervention Type OTHER

Caffeine

Subjects will be asked to increase caffeine intake by taking 200mg caffeine orally once per day.

Intervention Type DIETARY_SUPPLEMENT

Coffee

Subjects will be asked to increase coffee intake by drinking 2 cups (177 mL each) of coffee per day.

Intervention Type OTHER

Axon Eyewear

Subjects will be asked to utilize the therapeutic eyewear when exposed to bright or fluorescent light.

Intervention Type DEVICE

Chocolate

Subjects will be asked to increase chocolate intake by eating 57g per day.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Retinol Retinoic acid Pyridoxine Ascorbic acid Niacinamide Cholecalciferol α-tocopherol Brassica oleracea Spinacia oleracea 1,3,7-Trimethylpurine-2,6-dione

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* For BMI interventions, BMI \> 25
* For headache interventions, more than 2 headache-days per month
* For insomnia interventions, at least one day of self-reported poor sleep per week
* For rhinitis interventions, more than 2 days with symptoms per month
* For joint pain interventions, at least one day of self-reported joint pain per week

Exclusion Criteria

* Women who are pregnant, nursing or attempting to become pregnant
* Immediately life-threatening disease
* Current use of nutritional supplements of interest (excluded from those interventions to prevent overdose)
* For spinach interventions, gout
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Verifomics LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Brody Holohan, PhD

Role: PRINCIPAL_INVESTIGATOR

Verifomics LLC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Verifomics, LLC

Dallas, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

http://verifomics.com/

Website that begins the remote enrollment and participation process. Advertising material present on the site has been approved by the institutional review board.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

001

Identifier Type: -

Identifier Source: org_study_id